Is ONCT or VYM a better dividend investment in 2026?

ONCT currently yields 379.79% with a 5% 5-year dividend growth rate. VYM yields 2.41% with 7.8% growth. The better choice depends on your goal: ONCT offers higher current income.

What is the dividend yield difference between ONCT and VYM?

ONCT has a forward dividend yield of 379.79% ($2.00/share annually). VYM yields 2.41% ($3.51/share annually). The yield gap is 377.38 percentage points.

Home › Compare › ONCT vs VYM

ONCT vs VYM: Dividend Comparison 2026

ONCT yields 379.79% · VYM yields 2.41%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 ONCT wins by $7846.56M in total portfolio value

INVESTMENT

TIME HORIZON10 years

ONCT

● Live price

379.79%

Share price

$0.53

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$7846.59M

Annual income

$5,169,197,450.71

Full ONCT calculator →

VYM

Vanguard High Dividend Yield ETF

● Live price

2.41%

Share price

$145.48

Annual div

$3.51

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$27.8K

Annual income

$278.55

Full VYM calculator →

Portfolio growth — ONCT vs VYM

📍 ONCT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	ONCT	VYM
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, ONCT + VYM cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

ONCT pays

VYM pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ONCT

Annual income on $10K today (after 15% tax)

$32,282.57/yr

After 10yr DRIP, annual income (after tax)

$4,393,817,833.10/yr

VYM

Annual income on $10K today (after 15% tax)

$205.23/yr

After 10yr DRIP, annual income (after tax)

$236.77/yr

At 15% tax rate, ONCT beats the other by $4,393,817,596.34/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ONCT + VYM for your $10,000?

ONCT: 50%VYM: 50%

100% VYM50/50100% ONCT

Portfolio after 10yr

$3923.31M

Annual income

$2,584,598,864.62/yr

Blended yield

65.88%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ONCT buys

VYM buys

Politician	Chamber	Ticker	Type	Amount	Date
Carol Devine Miller	🏢 House	$VYM	▲ Buy	$15,001 - $50,000	2022-11-02

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricONCTVYM

Forward yield	379.79% ✓	2.41%
Annual dividend / share	$2.00	$3.51 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$7846.59M ✓	$27.8K
Annual income after 10y	$5,169,197,450.71 ✓	$278.55
Total dividends collected	$7596.65M ✓	$2.6K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: ONCT vs VYM ($10,000, DRIP)

Year	ONCT Portfolio	ONCT Income/yr	VYM Portfolio	VYM Income/yr	Gap
1← crossover	$48,679	$37,979.49	$11,151	$241.44	+$37.5K → ONCT
2	$224,874	$172,787.13	$12,413	$246.79	+$212.5K → ONCT
3	$986,585	$745,969.70	$13,794	$251.79	+$972.8K → ONCT
4	$4,114,314	$3,058,668.09	$15,306	$256.47	+$4.10M → ONCT
5	$16,323,283	$11,920,966.77	$16,960	$260.84	+$16.31M → ONCT
6	$61,667,489	$44,201,576.55	$18,768	$264.92	+$61.65M → ONCT
7	$222,048,216	$156,064,002.73	$20,745	$268.71	+$222.03M → ONCT
8	$762,773,776	$525,182,185.09	$22,905	$272.24	+$762.75M → ONCT
9	$2,502,234,339	$1,686,066,398.09	$25,265	$275.51	+$2502.21M → ONCT
10	$7,846,588,193	$5,169,197,450.71	$27,842	$278.55	+$7846.56M → ONCT

ONCT vs VYM: Complete Analysis 2026

ONCT — Stock

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.

Full ONCT Calculator →

VYM — ETF

Seeks to track the performance of the FTSE High Dividend Yield Index, which measures the investment return of common stocks of companies characterized by high dividend yields. Provides a convenient way to track the performance of stocks that are forecasted to have above-average dividend yields. Follows a passively managed, full-replication approach.

Full VYM Calculator →

📬

Get this ONCT vs VYM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ONCT vs SCHD ONCT vs JEPI ONCT vs O ONCT vs KO ONCT vs MAIN ONCT vs VIG ONCT vs DGRO ONCT vs HDV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.